Dorothy Mary Kate Keefe
Royal Adelaide Hospital
PathologyMucositisAutologous stem-cell transplantationDiarrheaChemotherapy-induced nausea and vomitingIrinotecanMedicine
What is this?
Publications 3
11607Background: Melphalan, remains the mainstay of conditioning for autologous hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and non-Hodgkin lymphoma (NHL) patients. Gast...
#1Mario E. Lacouture (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 52
#2Dorothy Mary Kate Keefe (Royal Adelaide Hospital)H-Index: 1
Last. Aminah Jatoi (Mayo Clinic)H-Index: 36
view all 9 authors...
e19049 Background: ARCHER 1042 (NCT01465802) was a randomized patient (pt) blinded trial that explored prophylactic interventions to minimize select dermatologic adverse events of interest (SDAEI) and diarrhea toxicities associated with D, an irreversible small molecule PanHER. Methods: In Cohorts I (CI) and II (CII) pts with advanced NSCLC, ≥ 1 prior chemo, ECOG 0–2, were randomized (pt blinded) in CI to (a) D 45 mg daily (QD) plus placebo (pbo) (D+pbo) or (b) D 45 mg QD plus doxy 100 mg twice ...
1 CitationsSource
e20580 Background: There are limited data on CINV in AP, a region diverse in healthcare systems and standards of care. The primary objective was to estimate the country-specific percentage of patients with complete response (CR: no emesis and no use of rescue medication) in the overall phase (0-120 hours) during cycle 1 by regimen emetogenicity. Methods: This was a prospective, observational study of highly and moderately emetogenic chemotherapy (HEC/MEC)-naive adults from 6 AP countries. Patien...